

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Date: April 21, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

BSE Scrip Code: 534920

ISIN: INE899M01020

Dear Sir / Madam,

Subject: Revised Outcome of the Meeting of the Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) (“the Company”) pursuant to Regulation 29 and 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to our prior intimation dated April 15, 2026 and deferment intimation dated April 20, 2026, and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI LODR Regulations**”) read with SEBI Master Circular No. HO/49/14/14(7)/2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform you that the Meeting of the Board of Directors of iSERA Lifesciences Limited (formerly known as Covidh Technologies Limited) (“**the Company**”) was held today, i.e., Tuesday, April 21, 2026, at the Registered Office of the Company situated at Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001, Maharashtra, wherein the Board of Directors, inter alia, considered and approved the following matters:

1. INCREASE IN AUTHORISED SHARE CAPITAL AND CONSEQUENTIAL ALTERATION OF CAPITAL CLAUSE OF MEMORANDUM OF ASSOCIATION

The Board of Directors considered and approved the increase in the Authorised Share Capital of the Company from Rs. 11,00,00,000/- (Rupees Eleven Crore Only) divided into 1,10,00,000 (One Crore Ten Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 25,00,00,000/- (Rupees Twenty-Five Crore Only) divided into 2,50,00,000 (Two Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each, by creation of 1,40,00,000 (One Crore Forty Lakh) additional Equity Shares of Rs. 10/- (Rupees Ten Only) each, and the consequential alteration of Clause V of the Memorandum of Association of the Company, subject to the approval of the Members of the Company by way of an Ordinary Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014.

2. ADOPTION OF NEW SET OF MEMORANDUM OF ASSOCIATION

The Board noted that the existing Memorandum of Association (“**MOA**”) of the Company is framed under the Companies Act, 1956 and requires to be aligned with the Companies Act, 2013 and the rules framed thereunder. Accordingly, the Board considered and approved the adoption of a new set of MOA in substitution of and to the entire exclusion of the existing MOA, subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014, details of which are described in **Annexure-A** attached hereto.

3. ADOPTION OF NEW SET OF ARTICLES OF ASSOCIATION

The Board noted that the existing Articles of Association (“**AOA**”) of the Company are framed under the Companies Act, 1956 and require to be aligned with the Companies Act, 2013 and the rules framed thereunder. Accordingly, the Board considered and approved the adoption of a new set of AOA in substitution of and to the entire exclusion of the existing AOA, subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014, details of which are described in **Annexure-A** attached hereto.

4. ENHANCEMENT OF LIMITS UNDER SECTION 186 OF THE COMPANIES ACT, 2013

The Board of Directors considered and approved the enhancement of the limit for making investments, giving loans or guarantees,

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

or providing security under Section 186 of the Companies Act, 2013, up to Rs. 1,000 Crore (Rupees One Thousand Crore Only), subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014.

5. APPROVAL OF VALUATION REPORT AND SWAP RATIO

The Board of Directors took on record and approved the following two Valuation Reports, both dated April 20, 2026, obtained by the Company in connection with the proposed preferential issue of equity shares on a Share Swap basis:

(a) Valuation Report for iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited):

Valuation Report issued by Mr. Bhavesh M Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708), determining the fair value of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) at Rs. 48.15/- (Rupees Forty-Eight and Paise Fifteen Only) per equity share. Since the equity shares of the Company are infrequently traded on BSE Limited in terms of Regulation 164(5) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), the said fair value of Rs. 48.15/- per share constitutes the floor price for the proposed preferential issue in terms of Regulation 164(2) of the SEBI ICDR Regulations. The Board confirmed that the issue price of Rs. 48.20/- per equity share, as determined on the basis of the said Valuation Report and the Swap Ratio, is not less than the floor price of Rs. 48.15/- per equity share computed in accordance with Regulation 164 of the SEBI ICDR Regulations.

(b) Valuation Report for iSERA Biological Limited:

Valuation Report issued by Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561), determining the fair value of equity shares of iSERA Biological Limited at Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share.

Swap Ratio:

| Particulars | Fair Value Per Share |
|--|---|
| iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) | Rs. 48.20/- |
| iSERA Biological Limited | Rs. 48.20/- |
| Swap Ratio | 1:1 (One equity share of iSERA Lifesciences Limited for every One equity share of iSERA Biological Limited) |

Accordingly, the issue price for the proposed preferential allotment of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has been fixed at Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of face value Rs. 10/- each (including a premium of Rs. 38.20/- per share), which is not less than the floor price determined under the SEBI ICDR Regulations.

The Valuation Reports shall be published on the website of the Company at www.covidhtechnologies.com in compliance with Regulation 166A(1) of the SEBI ICDR Regulations, and the details thereof shall form part of the Explanatory Statement to the Postal Ballot Notice to be dispatched to the Members of the Company.

6. APPROVAL OF RELATED PARTY TRANSACTION — ACQUISITION THROUGH SHARE SWAP

The Board of Directors noted that the Audit Committee of the Company, comprising only Independent Directors, at its meeting held on Monday, April 21, 2026, has granted its prior approval to the proposed Related Party Transaction ("RPT") in terms of Section 177 of the Companies Act, 2013 and the Company's Policy on Materiality of Related Party Transactions.

The Board, based on the recommendation of the Audit Committee and after satisfying itself that the proposed transaction is on an arm's length basis and in the best interests of the Company and its stakeholders, considered and approved the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited from its existing shareholders, who are related parties of the Company under Section 2(76) of the Companies Act, 2013, for a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged entirely by way of issuance and allotment of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of the Company at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of face value Rs. 10/- each, on a preferential basis for consideration other than cash (Share Swap), as certified by the Registered Valuers in the Valuation Reports dated April 20, 2026. Upon completion of the said acquisition, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

The said transaction constitutes a Related Party Transaction within the meaning of Section 2(76) of the Companies Act, 2013 and the Company's Policy on Materiality of Related Party Transactions. The approval of the Members of the Company is accordingly being sought by way of a Ordinary Resolution through Postal Ballot / Remote E-Voting, pursuant to Section 188 of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and in accordance with the Company's Policy on Materiality of Related Party Transactions. The Board further confirmed that all related parties, whether or not party to this transaction, shall not be entitled to vote on this resolution.

7. APPROVAL OF SHARE SWAP AGREEMENT

The Board of Directors considered and approved the Share Swap Agreement proposed to be executed between the Company and the shareholders of iSERA Biological Limited, in connection with the proposed acquisition of 100% of the paid-up equity share capital of iSERA Biological Limited through issue of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) on a preferential basis. The Board authorised the Directors, Key Managerial Personnel and the Company Secretary of the Company, severally, to finalise, execute and deliver the Share Swap Agreement and to do all such acts, deeds and things as may be necessary, desirable or expedient in connection therewith.

8. ACQUISITION OF UP TO 100% EQUITY SHAREHOLDING OF iSERA BIOLOGICAL LIMITED THROUGH SHARE SWAP

The Board of Directors considered and approved the acquisition of equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (an unlisted public company, CIN: U85300PN2016PLC165483), comprising up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares of face value Rs. 10/- (Rupees Ten Only) each, from the existing shareholders of iSERA Biological Limited, for a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged entirely by way of issuance and allotment of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per equity share of face value Rs. 10/- each (including a premium of Rs. 38.20/- per share), on a preferential basis for consideration other than cash (Share Swap), as certified by the Registered Valuers in the Valuation Reports dated April 20, 2026. The Swap Ratio has been determined at 1:1 (one equity share of iSERA Lifesciences Limited for every one equity share of iSERA Biological Limited). Upon completion of the said acquisition, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).

The acquisition is subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014, and receipt of In-Principle Approval from BSE Limited and such other regulatory approvals as may be required.

The details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure–B** to this outcome.

9. ISSUANCE OF EQUITY SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS FOR CONSIDERATION OTHER THAN CASH (SHARE SWAP)

Subject to the approval of the Members of the Company through Postal Ballot / Remote E-Voting and receipt of In-Principle Approval from BSE Limited and such other regulatory / governmental approvals as may be required, the Board of Directors considered and approved the issuance of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value Rs. 10/- (Rupees Ten Only) each at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per share (including a premium of Rs. 38.20/- (Rupees Thirty-Eight and Paise Twenty Only) per share), being a price not less than the floor price of Rs. 48.15/- per share determined in accordance with Regulation 164(2) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") (the equity shares of the Company being infrequently traded on BSE Limited in terms of Regulation 164(5) of the SEBI ICDR Regulations), to the existing shareholders of iSERA Biological Limited, for consideration other than cash (Share Swap), being the acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited, for an aggregate consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to be discharged entirely by way of issuance and allotment of the aforesaid equity shares of the Company. The issue price of Rs. 48.20/- per share has been determined on the basis of the Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/10708) in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), and Mr. Karan Chetan Shah, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2024/15561) in respect of iSERA Biological Limited, as required under Regulations 163(3) and 166A(1) of the SEBI ICDR

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Regulations.

The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 dated January 30, 2026, are enclosed herewith as **Annexure-C**.

10. APPROVAL OF NOTICE OF POSTAL BALLOT

The Board of Directors approved the draft Notice of Postal Ballot to seek the approval of the Members of the Company for the aforesaid matters. The Notice of Postal Ballot along with the Explanatory Statement will be dispatched separately to BSE Limited and to the Members of the Company and will also be available on the Company's website and on the website of BSE Limited in due course.

11. APPOINTMENT OF SCRUTINIZER FOR POSTAL BALLOT / REMOTE E-VOTING

The Board of Directors appointed CS Anuj Gupta, Practicing Company Secretary (Membership No.: 31025; COP No.: 13025), Proprietor of M/s Anuj Gupta & Associates, Company Secretaries, as the Scrutinizer to scrutinize the Postal Ballot / Remote E-Voting process in a fair and transparent manner, pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Meeting of the Board of Directors of the Company commenced at 11:00 A.M and concluded at 12:50 P.M.

We request you to kindly take the above information on record.

Thanking you,

Yours Faithfully,

For iSERA Lifesciences Limited

(Formerly known as Covidh Technologies Limited)

Deepakshi

Company Secretary and Compliance Officer Membership No.:

A76335

Place: Pune

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Annexure-A

Brief Details with respect to adoption of new set of Memorandum of Association of the Company

The existing Memorandum of Association (“MOA”) of the Company is framed under the Companies Act, 1956 (the “erstwhile Act”) and is required to be aligned with the Companies Act, 2013 and the rules framed thereunder. The alteration of MOA is necessary to bring it in conformity with the provisions of the new Act. The capital clause, object clause and liability clause of the existing MOA are required to be re-aligned as per Table A of Schedule I of the Companies Act, 2013. The revision in the main objects will provide enhanced clarity on the business activities of the Company and also provide the necessary flexibility to undertake any future business activity as may be mentioned in the objects.

Accordingly, the Board of Directors of the Company has considered and approved the adoption of a new set of Memorandum of Association in substitution of and to the entire exclusion of the existing Memorandum of Association of the Company, subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014.

Brief Details with respect to adoption of new set of Articles of Association of the Company

The existing Articles of Association (“AOA”) of the Company are framed under the provisions of the Companies Act, 1956 (the “erstwhile Act”) and several regulations in the existing AOA contain references to specific sections of the erstwhile Act. Some provisions in the existing AOA are no longer in conformity with the Companies Act, 2013 (the “new Act”) and the rules framed thereunder. In order to bring the existing AOA in line with the provisions of the new Act, the Company would be required to make numerous changes in the existing AOA. It is therefore considered necessary and desirable to adopt a comprehensive new set of Articles of Association of the Company in substitution of and to the entire exclusion of the existing Articles of Association.

Accordingly, the Board of Directors of the Company has considered and approved the adoption of a new set of Articles of Association in substitution of and to the entire exclusion of the existing Articles of Association of the Company, subject to the approval of the Members of the Company by way of a Special Resolution through Postal Ballot / Remote E-Voting pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014.

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Annexure-B

Disclosure in respect of Acquisition of up to 100% stake in iSERA Biological Limited, in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

| S. No. | Particulars | Details |
|--------|---|---|
| 1. | Name of the target entity, details in brief such as size, turnover etc., | <p>iSERA Biological Limited</p> <p>iSERA Biological Limited was incorporated on July 13, 2016, registered in Pune, with the Registrar of Companies, Pune, bearing CIN U85300PN2016PLC165483 and having its registered office at Falt-504, Bldg-A S No.- 671/2A/3, Bibwewadi, NA, Pune, Maharashtra-411037.</p> <p>The Target Company has achieved a Turnover of Rs.1835.97 lakhs for the year FY 2024-25.</p> |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”; | <p>Yes, the acquisition would fall within related party transaction as the Promoter / Promoter Group of the Company are the Director(s) / Shareholder(s) of iSERA Biological Limited.</p> <p>This transaction is being undertaken at arm’s length basis as certified by the Registered Valuer.</p> |
| 3. | Industry to which the entity being acquired belongs; | Pharmaceutical, Biotechnology and Life Sciences |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | <p>The acquisition of up to 100% equity shareholding of iSERA Biological Limited is in line with the Company’s strategic vision to expand and consolidate its presence in the pharmaceutical and life sciences sector. The business activities of iSERA Biological Limited complement the overall business profile of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) and the acquisition shall enable the Company to create synergistic value for its shareholders.</p> |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition; | Not Applicable |
| 6. | Indicative time period for completion of the acquisition; | Within 15 days from the later of: (i) receipt of Members’ approval through Postal Ballot / Remote E-Voting; or (ii) receipt of In-Principle Approval from BSE Limited, subject to such other regulatory approvals as may be required. |
| 7. | Nature of consideration - whether cash consideration | Swapping of shares i.e., Consideration other than Cash (Share Swap). |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | or share swap and details of the same; | <p>Preferential Issue of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) fully paid-up equity shares of face value Rs. 10/- (Rupees Ten Only) each of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited), at a price of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per share (including a premium of Rs. 38.20/- per share), aggregating to a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), to the existing shareholders of iSERA Biological Limited, for acquisition of up to 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) equity shares of face value Rs. 10/- (Rupees Ten Only) each of iSERA Biological Limited, representing up to 100% of the paid-up equity share capital of iSERA Biological Limited, at a fair value of Rs. 48.20/- (Rupees Forty-Eight and Paise Twenty Only) per share as certified by the Registered Valuer, giving a Swap Ratio of 1:1 (one equity share of iSERA Lifesciences Limited for every one equity share of iSERA Biological Limited). The entire consideration shall be discharged by way of issuance and allotment of equity shares of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) and no cash shall be paid or received by the Company in connection with this transaction.</p> | | | | | | | | | | | | |
|------------|---|---|-------------|------------|------------|------------|----------|--------------|-------------|-------------|--------|-------------|-------------|-------------|
| 8. | Cost of acquisition or the price at which the shares are acquired; | <p>Share Swap Ratio: 1:1 (One is to One) i.e., for every 1 (One) Equity Share of face value of Rs. 10/- each held by the existing Shareholder(s) in iSERA Biological Limited, such shareholder shall receive 1 (One) Equity Share of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) of face value Rs. 10/- each (as per the Valuation Reports dated April 20, 2026, issued by Mr. Bhavesh M Rathod, Registered Valuer, in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) and Mr. Karan Chetan Shah, Registered Valuer, in respect of iSERA Biological Limited).</p> | | | | | | | | | | | | |
| 9. | Percentage of shareholding/control acquired and/ or number of shares acquired; | <p>1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) Equity Shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited. Upon completion, iSERA Biological Limited shall become a Wholly Owned Subsidiary of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited).</p> | | | | | | | | | | | | |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | <p>a) Brief background: iSERA Biological Limited is engaged in the manufacture, import, export and trading of pharmaceutical, biological and biotechnological products including medicines, drugs, serums, vaccines, pharmaceutical formulations, regenerative medicines, stem cells and Ayurvedic products. The Company also undertakes research in genomics, proteomics, biotechnology, DNA recombinant technology and conjugation technology for development of human medicines, vaccines and biological products.</p> <p>b) Date of Incorporation: July 13, 2016</p> <p>c) Turnover and EBITDA for last 3 years:</p> <p style="text-align: right;">(In Rs.)</p> <table border="1"> <thead> <tr> <th>Particular</th> <th>FY 2024-25</th> <th>FY 2023-24</th> <th>FY 2022-23</th> </tr> </thead> <tbody> <tr> <td>Turnover</td> <td>18,35,97,170</td> <td>9,52,67,511</td> <td>7,41,21,691</td> </tr> <tr> <td>EBITDA</td> <td>7,67,49,887</td> <td>3,52,69,299</td> <td>2,96,37,835</td> </tr> </tbody> </table> <p>d) The entity has its presence only in India. Any other significant information: N.A.</p> | Particular | FY 2024-25 | FY 2023-24 | FY 2022-23 | Turnover | 18,35,97,170 | 9,52,67,511 | 7,41,21,691 | EBITDA | 7,67,49,887 | 3,52,69,299 | 2,96,37,835 |
| Particular | FY 2024-25 | FY 2023-24 | FY 2022-23 | | | | | | | | | | | |
| Turnover | 18,35,97,170 | 9,52,67,511 | 7,41,21,691 | | | | | | | | | | | |
| EBITDA | 7,67,49,887 | 3,52,69,299 | 2,96,37,835 | | | | | | | | | | | |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Annexure-C

Disclosure in respect of the Preferential Issue, in terms of Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

| S. No. | Particulars | Details | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--|---|---|----------|---|---|--|--|--|---|-------------------------|----------|-----------|---|----------------------|----------|-----------|---|---------------------------|----------|----------|---|--------------------|----------|----------|---|--------------------------|----------|----------|---|-------------------------|----------|----------|---|------------------------------|----------|----------|---|-----------------------|----------------|----------|---|-----------------------|----------------|----------|----|----------------------|----------------|----------|----|-----------------------|----------------|----------|----|--------------|----------------|----------|----|---------------------|----------------|----------|----|-------------------|----------------|----------|----|------------------------|----------------|----------|----|----------------------|----------------|----------|----|---------------------------|----------------|--------|----|----------------------------|----------------|--------|----|------------------|----------------|--------|----|----------------------------|----------------|--------|----|-------------------------|----------------|--------|----|---------------------|----------------|--------|----|------------------------|----------------|--------|----|---------------------------|----------------|--------|----|--------------------|----------------|--------|
| 1. | Type of securities proposed to be issued | Equity Shares | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2. | Type of issuance | Preferential allotment | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3. | Total number of securities Proposed to be issued or the total amount for which the securities will be issued | 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) Equity Shares of face value Rs. 10/- each of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) to the existing shareholders (Promoter and Non-Promoter) of iSERA Biological Limited on a Share Swap basis as per valuation done by the Registered Valuer. The present issue is for consideration other than cash, i.e., through swap of shares. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4. | In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| a. | Name of the Investors | The names of the Proposed Allottees are : <table border="1"><thead><tr><th>S. No.</th><th>Names of the Propose Allottees/ Investors</th><th>Category</th><th>No of Equity Shares proposed to be issued</th></tr></thead><tbody><tr><td colspan="4">Promoter & Promoter Group Allottees:</td></tr><tr><td>1</td><td>SHUBHANGI DHANRAJ GARAD</td><td>Promoter</td><td>27,55,000</td></tr><tr><td>2</td><td>SUMEET DHANRAJ GARAD</td><td>Promoter</td><td>11,92,000</td></tr><tr><td>3</td><td>PRATAP DADASAHEB DESHMUKH</td><td>Promoter</td><td>7,85,500</td></tr><tr><td>4</td><td>RITU DHANRAJ GARAD</td><td>Promoter</td><td>7,46,000</td></tr><tr><td>5</td><td>ARCHANA KAKASAHEB LONKAR</td><td>Promoter</td><td>4,95,000</td></tr><tr><td>6</td><td>NANDKUMAR SUBHASH KADAM</td><td>Promoter</td><td>4,56,500</td></tr><tr><td>7</td><td>DHAIRYASHEEL VASANTRAO YADAV</td><td>Promoter</td><td>4,50,500</td></tr><tr><td>8</td><td>VENKATESH MADHAV BHAT</td><td>Promoter Group</td><td>1,50,000</td></tr><tr><td>9</td><td>PRAVIN VAMAN SURYARAO</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>10</td><td>MADAN MANOHAR BALLAL</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>11</td><td>DARSHANA VIKAS CHAVAN</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>12</td><td>AADHAR KUMAR</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>13</td><td>ISHITA RAJESH KUMAR</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>14</td><td>UJJWALA ANIL MANE</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>15</td><td>JYOTI MANESH WAGHIRKAR</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>16</td><td>ARCHANA SITARAM KALE</td><td>Promoter Group</td><td>1,00,000</td></tr><tr><td>17</td><td>BABASAHEB MAHADEO BHOSALE</td><td>Promoter Group</td><td>80,000</td></tr><tr><td>18</td><td>SANJAY RAMCHANDRA TARLEKAR</td><td>Promoter Group</td><td>75,000</td></tr><tr><td>19</td><td>ANITA SUNIL NAIR</td><td>Promoter Group</td><td>75,000</td></tr><tr><td>20</td><td>KAMLAKAR NIVRUTTI DANDWATE</td><td>Promoter Group</td><td>70,000</td></tr><tr><td>21</td><td>SANJIV DATTATRAY JADHAV</td><td>Promoter Group</td><td>50,000</td></tr><tr><td>22</td><td>SHITAL TUSHAR PAWAR</td><td>Promoter Group</td><td>50,000</td></tr><tr><td>23</td><td>SANTOSH MADHAVRAV NAIK</td><td>Promoter Group</td><td>50,000</td></tr><tr><td>24</td><td>YOGESH INDRAJIT SOMWANSHI</td><td>Promoter Group</td><td>50,000</td></tr><tr><td>25</td><td>LATA SANJIV JADHAV</td><td>Promoter Group</td><td>50,000</td></tr></tbody></table> | S. No. | Names of the Propose Allottees/ Investors | Category | No of Equity Shares proposed to be issued | Promoter & Promoter Group Allottees: | | | | 1 | SHUBHANGI DHANRAJ GARAD | Promoter | 27,55,000 | 2 | SUMEET DHANRAJ GARAD | Promoter | 11,92,000 | 3 | PRATAP DADASAHEB DESHMUKH | Promoter | 7,85,500 | 4 | RITU DHANRAJ GARAD | Promoter | 7,46,000 | 5 | ARCHANA KAKASAHEB LONKAR | Promoter | 4,95,000 | 6 | NANDKUMAR SUBHASH KADAM | Promoter | 4,56,500 | 7 | DHAIRYASHEEL VASANTRAO YADAV | Promoter | 4,50,500 | 8 | VENKATESH MADHAV BHAT | Promoter Group | 1,50,000 | 9 | PRAVIN VAMAN SURYARAO | Promoter Group | 1,00,000 | 10 | MADAN MANOHAR BALLAL | Promoter Group | 1,00,000 | 11 | DARSHANA VIKAS CHAVAN | Promoter Group | 1,00,000 | 12 | AADHAR KUMAR | Promoter Group | 1,00,000 | 13 | ISHITA RAJESH KUMAR | Promoter Group | 1,00,000 | 14 | UJJWALA ANIL MANE | Promoter Group | 1,00,000 | 15 | JYOTI MANESH WAGHIRKAR | Promoter Group | 1,00,000 | 16 | ARCHANA SITARAM KALE | Promoter Group | 1,00,000 | 17 | BABASAHEB MAHADEO BHOSALE | Promoter Group | 80,000 | 18 | SANJAY RAMCHANDRA TARLEKAR | Promoter Group | 75,000 | 19 | ANITA SUNIL NAIR | Promoter Group | 75,000 | 20 | KAMLAKAR NIVRUTTI DANDWATE | Promoter Group | 70,000 | 21 | SANJIV DATTATRAY JADHAV | Promoter Group | 50,000 | 22 | SHITAL TUSHAR PAWAR | Promoter Group | 50,000 | 23 | SANTOSH MADHAVRAV NAIK | Promoter Group | 50,000 | 24 | YOGESH INDRAJIT SOMWANSHI | Promoter Group | 50,000 | 25 | LATA SANJIV JADHAV | Promoter Group | 50,000 |
| S. No. | Names of the Propose Allottees/ Investors | Category | No of Equity Shares proposed to be issued | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Promoter & Promoter Group Allottees: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | SHUBHANGI DHANRAJ GARAD | Promoter | 27,55,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | SUMEET DHANRAJ GARAD | Promoter | 11,92,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | PRATAP DADASAHEB DESHMUKH | Promoter | 7,85,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | RITU DHANRAJ GARAD | Promoter | 7,46,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | ARCHANA KAKASAHEB LONKAR | Promoter | 4,95,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | NANDKUMAR SUBHASH KADAM | Promoter | 4,56,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | DHAIRYASHEEL VASANTRAO YADAV | Promoter | 4,50,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | VENKATESH MADHAV BHAT | Promoter Group | 1,50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | PRAVIN VAMAN SURYARAO | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | MADAN MANOHAR BALLAL | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | DARSHANA VIKAS CHAVAN | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | AADHAR KUMAR | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13 | ISHITA RAJESH KUMAR | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | UJJWALA ANIL MANE | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | JYOTI MANESH WAGHIRKAR | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16 | ARCHANA SITARAM KALE | Promoter Group | 1,00,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17 | BABASAHEB MAHADEO BHOSALE | Promoter Group | 80,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18 | SANJAY RAMCHANDRA TARLEKAR | Promoter Group | 75,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 19 | ANITA SUNIL NAIR | Promoter Group | 75,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 | KAMLAKAR NIVRUTTI DANDWATE | Promoter Group | 70,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 21 | SANJIV DATTATRAY JADHAV | Promoter Group | 50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 22 | SHITAL TUSHAR PAWAR | Promoter Group | 50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 23 | SANTOSH MADHAVRAV NAIK | Promoter Group | 50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 24 | YOGESH INDRAJIT SOMWANSHI | Promoter Group | 50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 25 | LATA SANJIV JADHAV | Promoter Group | 50,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | |
|----|---|----------------|-----------|
| 26 | SUNITA SANTOSH PATIL | Promoter Group | 30,000 |
| 27 | SUMAN RAVINDRA KUNJIR | Promoter Group | 30,000 |
| 28 | SADHANA DIGAMBAR JOSHI | Promoter Group | 25,000 |
| 29 | DILIP GANESH KULKARNI | Promoter Group | 25,000 |
| 30 | ANANT KAMLAKAR DANDAWATE | Promoter Group | 25,000 |
| 31 | REKHA ANIL PATIL | Promoter Group | 20,000 |
| 32 | DR PATIL SACHIN SHRIDHAR | Promoter Group | 10,000 |
| 33 | MILIND YOGESHWAR BAM | Promoter Group | 10,000 |
| 34 | NITIN RAMESH KULKARNI | Promoter Group | 10,000 |
| 35 | NIRANJAN VINAYAK DESHPANDE | Promoter Group | 10,000 |
| 36 | AMBADAS DATTATRAYA SHINDE | Promoter Group | 10,000 |
| 37 | JITENDRA PRABHAKAR NENE | Promoter Group | 10,000 |
| 38 | ABHIJIT MAHADEV VEER | Promoter Group | 10,000 |
| 39 | PRASAD DILIP NAGARE | Promoter Group | 7,500 |
| | Non-Promoter Allottees: | | |
| 40 | VINEET ARORA | Non - Promoter | 1,41,600 |
| 41 | KUNAL DEEPAK AGASHE | Non - Promoter | 1,07,600 |
| 42 | NEVILLE MANECKJI | Non - Promoter | 99,400 |
| 43 | DEVANATHAN GOVINDARAJAN | Non - Promoter | 91,600 |
| 44 | RAVI NATHAN IYER | Non - Promoter | 91,600 |
| 45 | DARSHAN GANGOLLI | Non - Promoter | 83,200 |
| 46 | MANGINA S RAO | Non - Promoter | 41,600 |
| 47 | AMOGH GIRISH BRAHME | Non - Promoter | 30,400 |
| 48 | DAMINI SANDEEP GHATE | Non - Promoter | 27,200 |
| 49 | MAYUR PRAKASH KARDILE | Non - Promoter | 25,600 |
| 50 | PARTH YASHODHAN WANAGE | Non - Promoter | 25,000 |
| 51 | UMA SANDEEP GHATE | Non - Promoter | 20,800 |
| 52 | PRATIK SHUBHKARAN SANGHI | Non - Promoter | 20,000 |
| 53 | MANSHA NIKHIL CHAWLA | Non - Promoter | 13,000 |
| 54 | SANJAY EKNATH BHOSALE | Non - Promoter | 11,200 |
| 55 | RAHUL HEMANTKUMAR MEHTA | Non - Promoter | 8,000 |
| 56 | JYOTI KETAN VAKHARIA | Non - Promoter | 1,86,400 |
| 57 | NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND | Non - Promoter | 10,00,000 |
| 58 | M7 GLOBAL FUND PCC - CELL DEWCAP FUND | Non - Promoter | 4,24,800 |
| 59 | SAURAV RAIDANI | Non - Promoter | 3,08,000 |
| 60 | JAYARAMAN VISHWANATHAN | Non - Promoter | 2,16,000 |
| 61 | RAJESH CHANDRAKANT VAISHNAV | Non - Promoter | 2,00,000 |
| 62 | MORDE FOODS PRIVATE LIMITED | Non - Promoter | 2,00,000 |
| 63 | ERINOME ADVISORS LLP | Non - Promoter | 2,00,000 |
| 64 | GUHAPRIYA SRIDHAR | Non - Promoter | 1,90,000 |
| 65 | ASMITA ROHAN PAI | Non - Promoter | 1,75,000 |
| 66 | EUDORA VENTURES LLP | Non - Promoter | 1,50,000 |
| 67 | DOVETAIL GLOBAL FUND PCC ALL SEASONS INDIA OPPORTUNITIES FUND | Non - Promoter | 1,50,000 |
| 68 | DEEPAK AGASHE HUF | Non - Promoter | 1,41,600 |
| 69 | SHANTI KALIAPPAN | Non - Promoter | 1,41,600 |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | |
|-----|--|----------------|----------|
| 70 | FAT PANDA REALTY LLP | Non - Promoter | 1,30,000 |
| 71 | SHEETAL MEHTA | Non - Promoter | 1,16,600 |
| 72 | RAHUL CHANDRASINGH MEHTA | Non - Promoter | 1,06,600 |
| 73 | MARIETTA BARRETO | Non - Promoter | 1,00,000 |
| 74 | 3STATE VENTURES PTE. LTD. | Non - Promoter | 1,00,000 |
| 75 | NIKHIL TYAGI | Non - Promoter | 1,00,000 |
| 76 | AMIT J DHOLAKIA HUF | Non - Promoter | 1,00,000 |
| 77 | VISHAL ULHAS DHUMAL | Non - Promoter | 87,000 |
| 78 | DEEPSHIKHA ARORA | Non - Promoter | 83,200 |
| 79 | SAJID UMEDALI DHROLIA | Non - Promoter | 83,200 |
| 80 | KULBHUSHAN PARASHAR | Non - Promoter | 83,200 |
| 81 | ANURADHA HARSHAL MORDE | Non - Promoter | 83,200 |
| 82 | REX EQUITY | Non - Promoter | 83,200 |
| 83 | KALAWATI KISHOR THAKKAR | Non - Promoter | 80,000 |
| 84 | SUNIL POPATLAL NAHAR | Non - Promoter | 66,600 |
| 85 | RASHMI YASHDEEP JOSHI | Non - Promoter | 60,000 |
| 86 | BHAVNA GOTHI | Non - Promoter | 50,000 |
| 87 | MUKKTA NEVILLE MANECKJI | Non - Promoter | 50,000 |
| 88 | VIKAS ARORA | Non - Promoter | 50,000 |
| 89 | ABHAY PRABHAKAR HAVALDAR | Non - Promoter | 50,000 |
| 90 | MALIK AMIRBHAI CHARANIYA | Non - Promoter | 49,600 |
| 91 | ASHOK BHAWANDAS AWTANI | Non - Promoter | 42,600 |
| 92 | DIVESH WADHAWAN | Non - Promoter | 41,600 |
| 93 | NETRADEEP EYE HOSPITAL PRIVATE LTD | Non - Promoter | 41,600 |
| 94 | AMISHA NIRAJ VORA | Non - Promoter | 41,600 |
| 95 | NERGIS GAURAV PARIKH | Non - Promoter | 41,600 |
| 96 | SAROD REALITY PRIVATE LIMITED | Non - Promoter | 41,600 |
| 97 | PRATIM SENGUPTA | Non - Promoter | 41,600 |
| 98 | BIJAL KUNAL THAKKAR | Non - Promoter | 37,600 |
| 99 | SIDDARTH MURALI KONTHATH | Non - Promoter | 33,600 |
| 100 | JASPRIT J BUMRAH | Non - Promoter | 33,600 |
| 101 | SHILPA ASHWIN RANGDAL | Non - Promoter | 33,600 |
| 102 | VINIT BIPIN SHAH | Non - Promoter | 33,600 |
| 103 | ROHIT SHARMA | Non - Promoter | 33,600 |
| 104 | DILIP KESHRIKAL SANKLECHA | Non - Promoter | 25,000 |
| 105 | CHANDRASHEKHAR RAJARAM KULKARNI | Non - Promoter | 20,000 |
| 106 | AAMIR KHAN | Non - Promoter | 17,600 |
| 107 | KANNAN KRISHNAMURTI NAIDU | Non - Promoter | 17,600 |
| 108 | CHANNA KESHAVA HOSAGAVI | Non - Promoter | 16,000 |
| 109 | RANBIR RISHI KAPOOR | Non - Promoter | 16,000 |
| 110 | SHILPA NARENDRA HIRANI | Non - Promoter | 16,000 |
| 111 | BIMAL PAREKH | Non - Promoter | 16,000 |
| 112 | KINGSMAN WEALTH MANAGEMENT PRIVATE LIMITED | Non - Promoter | 16,000 |
| 113 | SUNIL GOVINDLAL BHANDARI | Non - Promoter | 16,000 |
| 114 | JASKARAN SINGH | Non - Promoter | 16,000 |
| 115 | KISHORE KANJI THAKKAR | Non - Promoter | 16,000 |
| 116 | ARUN MAFATLAL PRAJAPATI | Non - Promoter | 16,000 |
| 117 | BIBHAS DASGUPTA | Non - Promoter | 16,000 |
| 118 | MANOJ BAVANJIBHAI | Non - Promoter | 16,000 |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | BAVARIA | | |
|-----|----------------------------------|----------------|--------|
| 119 | AJAY AGNIHOTRI | Non - Promoter | 16,000 |
| 120 | JYOTSNA MEHTA | Non - Promoter | 15,100 |
| 121 | MANOJ SHIV LAUNGANI | Non - Promoter | 15,000 |
| 122 | SHALINI ASHOK CHAWLA | Non - Promoter | 13,000 |
| 123 | ANKITA CHOPRA | Non - Promoter | 12,800 |
| 124 | AXE FORTUNE CAPITAL ADVISORS LLP | Non - Promoter | 12,800 |
| 125 | ABHISHEK NARBARIA | Non - Promoter | 12,800 |
| 126 | UMESH KUMAR SAHAY | Non - Promoter | 12,800 |
| 127 | RESHMA MANOJ MOHNANI | Non - Promoter | 12,800 |
| 128 | RASHMI SARAFF | Non - Promoter | 10,000 |
| 129 | DINESHKUMAR S RAWLANI | Non - Promoter | 9,600 |
| 130 | SETHIYA SACHIN KANTILAL | Non - Promoter | 9,600 |
| 131 | ESHA SAVLANI | Non - Promoter | 9,600 |
| 132 | S NAGESHWARAN | Non - Promoter | 8,000 |
| 133 | MINDSCOPE ADVISORS LLP | Non - Promoter | 8,000 |
| 134 | MUKESH MANOHAR YEOLE | Non - Promoter | 8,000 |
| 135 | SRINIVASAN ROHINI | Non - Promoter | 8,000 |
| 136 | ILESH H SANGHANI | Non - Promoter | 8,000 |
| 137 | ARWA ALVARES | Non - Promoter | 8,000 |
| 138 | LADDHA NIKHIL RAMESHKUMAR | Non - Promoter | 8,000 |
| 139 | BHAKTI BIMAL PAREKH | Non - Promoter | 8,000 |
| 140 | PRANAV NAVINCHANDRA DOCTOR | Non - Promoter | 8,000 |
| 141 | KALLAM SRINIVAS REDDY | Non - Promoter | 8,000 |
| 142 | NEELA GOPALAKRISHNAN | Non - Promoter | 8,000 |
| 143 | WINNER IMPEX PVT LTD | Non - Promoter | 8,000 |
| 144 | PRAGNESH A SHAH | Non - Promoter | 8,000 |
| 145 | PARUL KARTIK VAKHARIA | Non - Promoter | 8,000 |
| 146 | KRISHNAKUMAR RATANKUMAR MOHTA | Non - Promoter | 8,000 |
| 147 | NIMISHA GORAKSHAKAR | Non - Promoter | 8,000 |
| 148 | SUNIL SURESHCHANDRA PHADE | Non - Promoter | 8,000 |
| 149 | KAPIL DHIRAJ THAKKAR | Non - Promoter | 8,000 |
| 150 | TAPAS SAHA | Non - Promoter | 8,000 |
| 151 | MAULALI CHANDSAHEB JAMADAR | Non - Promoter | 8,000 |
| 152 | AAMER DE | Non - Promoter | 8,000 |
| 153 | DHANANJAY PUNDLIK WAKUDKAR | Non - Promoter | 8,000 |
| 154 | SRIRAM JEYARAMAN HUF | Non - Promoter | 8,000 |
| 155 | VINAY KUMAR | Non - Promoter | 8,000 |
| 156 | GIRISH PUKHRAJ PORWAL | Non - Promoter | 8,000 |
| 157 | MUKESH BHAGWANLAL SHINGI | Non - Promoter | 8,000 |
| 158 | MANISH SHANKARLAL RATHI | Non - Promoter | 8,000 |
| 159 | SAHAJ BIMAL PAREKH | Non - Promoter | 8,000 |
| 160 | SAMPATH KUMAR AMUDHA | Non - Promoter | 6,400 |
| 161 | PONNAKATTI RAJAN UDAY KUMAR | Non - Promoter | 6,400 |
| 162 | PONNAGATIKUPPUSWAMY JAYARAMAN | Non - Promoter | 6,400 |
| 163 | PONNAI CHOKALINGAM MANI | Non - Promoter | 6,400 |
| 164 | JAYANT DIGAMBAR PATKAR | Non - Promoter | 6,400 |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | |
|-----|-------------------------------------|----------------|-------|
| 165 | NEHA ALTAMASH AHMED | Non - Promoter | 6,400 |
| 166 | PRANAY PRITHVIRAJ CHOUHAN | Non - Promoter | 6,400 |
| 167 | NRIP NIHALANI | Non - Promoter | 6,400 |
| 168 | VERSHA SHARMA | Non - Promoter | 6,400 |
| 169 | ASHISH SURJEET MAKHIJANI | Non - Promoter | 6,400 |
| 170 | MURALI NAGARAJAN | Non - Promoter | 6,400 |
| 171 | KARAN RAJEEV GOYAL | Non - Promoter | 6,400 |
| 172 | ROSHAAN MADHUKAR NARKEDAYY | Non - Promoter | 6,400 |
| 173 | ARCHANA AMAR MULE | Non - Promoter | 6,400 |
| 174 | VINAYAK CHANDRAKANT SANAS | Non - Promoter | 6,400 |
| 175 | RAM PRASAD LADI | Non - Promoter | 6,400 |
| 176 | SHIFA MAKSUD MULANI | Non - Promoter | 6,400 |
| 177 | SIDDARTH JAIN | Non - Promoter | 6,400 |
| 178 | SIDDHANT MANGESH DOSHI | Non - Promoter | 6,400 |
| 179 | ADITYA VIVEK PATKAR | Non - Promoter | 6,400 |
| 180 | SAMARTH MEHTA | Non - Promoter | 5,500 |
| 181 | RAJA JEPPEAN | Non - Promoter | 5,000 |
| 182 | KATTELA RAMESH | Non - Promoter | 5,000 |
| 183 | SAHIL MEHTA | Non - Promoter | 5,000 |
| 184 | SHRIKANT LAXMAN KHAJGIWALE | Non - Promoter | 4,800 |
| 185 | PRASANNA SHRIKANT KHAJGIWALE | Non - Promoter | 4,800 |
| 186 | ATUL KANTILAL SHAH | Non - Promoter | 4,600 |
| 187 | KETAN PRAVEEN RANGA | Non - Promoter | 4,000 |
| 188 | RAKESH PRAKASH SHARMA | Non - Promoter | 4,000 |
| 189 | THURUPHATI SHEKAR | Non - Promoter | 3,200 |
| 190 | KARTHIKEYAN BALAKRISHNA | Non - Promoter | 3,200 |
| 191 | MASILAMANI NARAYANASWAMY PONNANGATI | Non - Promoter | 3,200 |
| 192 | MOHAN RAO AVANURI | Non - Promoter | 3,200 |
| 193 | GIRIPRASAD NARAYANAN | Non - Promoter | 3,200 |
| 194 | KALIYUR SELVAMANI RAMANUJAM | Non - Promoter | 3,200 |
| 195 | ANSHUL ABHISHEK | Non - Promoter | 3,200 |
| 196 | LOGANATHAN MEENAKSHISUNDARAM | Non - Promoter | 3,200 |

| | | | | | | |
|----|--|--|---|-------|--|--------|
| b. | Post allotment of Securities — outcome of the subscription | Details of the shareholding of the Proposed Allottees in the Company, prior to and after the Preferential Issue, are as under: | | | | |
| | | Proposed Allottee | Pre-Preferential Issue Shareholding & Percentage | | Post-preferential Issue Shareholding & Percentage | |
| | | | Shares | % | Shares | % |
| | | Promoter and Promoter Group Allottees: | | | | |
| | | SHUBHANGI DHANRAJ GARAD | 8,00,000 | 9.51% | 35,55,000 | 14.46% |
| | | SUMEET DHANRAJ GARAD | 1,00,000 | 1.19% | 12,92,000 | 5.25% |
| | | PRATAP DADASAHEB DESHMUKH | 5,50,000 | 6.54% | 13,35,500 | 5.43% |
| | | RITU DHANRAJ GARAD | 1,00,000 | 1.19% | 8,46,000 | 3.44% |
| | | ARCHANA KAKASAHEB LONKAR | 7,00,000 | 8.32% | 11,95,000 | 4.86% |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | | |
|--------------------------------|-----------|--------|-----------|-------|
| NANDKUMAR SUBHASH KADAM | 11,15,000 | 13.26% | 15,71,500 | 6.39% |
| DHAIRYASHEEL VASANTRAO YADAV | 11,15,000 | 13.26% | 15,65,500 | 6.37% |
| VENKATESH MADHAV BHAT | 0 | 0.00% | 1,50,000 | 0.61% |
| PRAVIN VAMAN SURYARAO | 0 | 0.00% | 1,00,000 | 0.41% |
| MADAN MANOHAR BALLAL | 0 | 0.00% | 1,00,000 | 0.41% |
| DARSHANA VIKAS CHAVAN | 0 | 0.00% | 1,00,000 | 0.41% |
| AADHAR KUMAR | 0 | 0.00% | 1,00,000 | 0.41% |
| ISHITA RAJESH KUMAR | 0 | 0.00% | 1,00,000 | 0.41% |
| UJJWALA ANIL MANE | 0 | 0.00% | 1,00,000 | 0.41% |
| JYOTI MANESH WAGHIRKAR | 0 | 0.00% | 1,00,000 | 0.41% |
| ARCHANA SITARAM KALE | 0 | 0.00% | 1,00,000 | 0.41% |
| BABASAHEB MAHADEO BHOSALE | 0 | 0.00% | 80,000 | 0.33% |
| SANJAY RAMCHANDRA TARLEKAR | 0 | 0.00% | 75,000 | 0.30% |
| ANITA SUNIL NAIR | 0 | 0.00% | 75,000 | 0.30% |
| KAMLAKAR NIVRUTTI DANDWATE | 0 | 0.00% | 70,000 | 0.28% |
| SANJIV DATTATRAY JADHAV | 0 | 0.00% | 50,000 | 0.20% |
| SHITAL TUSHAR PAWAR | 0 | 0.00% | 50,000 | 0.20% |
| SANTOSH MADHAVRAV NAIK | 0 | 0.00% | 50,000 | 0.20% |
| YOGESH INDRAJIT SOMWANSHI | 0 | 0.00% | 50,000 | 0.20% |
| LATA SANJIV JADHAV | 0 | 0.00% | 50,000 | 0.20% |
| SUNITA SANTOSH PATIL | 0 | 0.00% | 30,000 | 0.12% |
| SUMAN RAVINDRA KUNJIR | 0 | 0.00% | 30,000 | 0.12% |
| SADHANA DIGAMBAR JOSHI | 0 | 0.00% | 25,000 | 0.10% |
| DILIP GANESH KULKARNI | 0 | 0.00% | 25,000 | 0.10% |
| ANANT KAMLAKAR DANDAWATE | 0 | 0.00% | 25,000 | 0.10% |
| REKHA ANIL PATIL | 0 | 0.00% | 20,000 | 0.08% |
| DR PATIL SACHIN SHRIDHAR | 0 | 0.00% | 10,000 | 0.04% |
| MILIND YOGESHWAR BAM | 0 | 0.00% | 10,000 | 0.04% |
| NITIN RAMESH KULKARNI | 0 | 0.00% | 10,000 | 0.04% |
| NIRANJAN VINAYAK DESHPANDE | 0 | 0.00% | 10,000 | 0.04% |
| AMBADAS DATTATRAYA SHINDE | 0 | 0.00% | 10,000 | 0.04% |
| JITENDRA PRABHAKAR NENE | 0 | 0.00% | 10,000 | 0.04% |
| ABHIJIT MAHADEV VEER | 0 | 0.00% | 10,000 | 0.04% |
| PRASAD DILIP NAGARE | 0 | 0.00% | 7,500 | 0.03% |
| Non-Promoter Allottees: | | | | |
| VINEET ARORA | 75,000 | 0.89% | 2,16,600 | 0.88% |
| KUNAL DEEPAK AGASHE | 1,00,000 | 1.19% | 2,07,600 | 0.84% |
| NEVILLE MANECKJI | 3,62,500 | 4.31% | 4,61,900 | 1.88% |
| DEVANATHAN GOVINDARAJAN | 15,000 | 0.18% | 1,06,600 | 0.43% |
| RAVI NATHAN IYER | 15,000 | 0.18% | 1,06,600 | 0.43% |
| DARSHAN GANGOLLI | 15,000 | 0.18% | 98,200 | 0.40% |
| MANGINA S RAO | 10,000 | 0.12% | 51,600 | 0.21% |
| AMOGH GIRISH BRAHME | 25,000 | 0.30% | 55,400 | 0.23% |
| DAMINI SANDEEP GHATE | 75,000 | 0.89% | 1,02,200 | 0.42% |
| MAYUR PRAKASH KARDILE | 20,000 | 0.24% | 45,600 | 0.19% |
| PARTH YASHODHAN WANAGE | 68,750 | 0.82% | 93,750 | 0.38% |
| UMA SANDEEP GHATE | 75,000 | 0.89% | 95,800 | 0.39% |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | | | |
|--|---|--------|-------|-----------|-------|
| | PRATIK SHUBHKARAN SANGHI | 20,000 | 0.24% | 40,000 | 0.16% |
| | MANSHA NIKHIL CHAWLA | 25,000 | 0.30% | 38,000 | 0.15% |
| | SANJAY EKNATH BHOSALE | 25,000 | 0.30% | 36,200 | 0.15% |
| | RAHUL HEMANTKUMAR MEHTA | 25,000 | 0.30% | 33,000 | 0.13% |
| | JYOTI KETAN VAKHARIA | 15,000 | 0.18% | 2,01,400 | 0.82% |
| | NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND | 0 | 0.00% | 10,00,000 | 4.07% |
| | M7 GLOBAL FUND PCC - CELL DEWCAP FUND | 0 | 0.00% | 4,24,800 | 1.73% |
| | SAURAV RAIDANI | 0 | 0.00% | 3,08,000 | 1.25% |
| | JAYARAMAN VISHWANATHAN | 0 | 0.00% | 2,16,000 | 0.88% |
| | RAJESH CHANDRAKANT VAISHNAV | 0 | 0.00% | 2,00,000 | 0.81% |
| | MORDE FOODS PRIVATE LIMITED | 0 | 0.00% | 2,00,000 | 0.81% |
| | ERINOME ADVISORS LLP | 0 | 0.00% | 2,00,000 | 0.81% |
| | GUHAPRIYA SRIDHAR | 0 | 0.00% | 1,90,000 | 0.77% |
| | ASMITA ROHAN PAI | 0 | 0.00% | 1,75,000 | 0.71% |
| | EUDORA VENTURES LLP | 0 | 0.00% | 1,50,000 | 0.61% |
| | DOVETAIL GLOBAL FUND PCC ALL SEASONS INDIA OPPORTUNITIES FUND | 0 | 0.00% | 1,50,000 | 0.61% |
| | DEEPAK AGASHE HUF | 0 | 0.00% | 1,41,600 | 0.58% |
| | SHANTI KALIAPPAN | 0 | 0.00% | 1,41,600 | 0.58% |
| | FAT PANDA REALTY LLP | 0 | 0.00% | 1,30,000 | 0.53% |
| | SHEETAL MEHTA | 0 | 0.00% | 1,16,600 | 0.47% |
| | RAHUL CHANDRASINGH MEHTA | 0 | 0.00% | 1,06,600 | 0.43% |
| | MARIETTA BARRETO | 0 | 0.00% | 1,00,000 | 0.41% |
| | 3STATE VENTURES PTE. LTD. | 0 | 0.00% | 1,00,000 | 0.41% |
| | NIKHIL TYAGI | 0 | 0.00% | 1,00,000 | 0.41% |
| | AMIT J DHOLAKIA HUF | 0 | 0.00% | 1,00,000 | 0.41% |
| | VISHAL ULHAS DHUMAL | 0 | 0.00% | 87,000 | 0.35% |
| | DEEPSHIKHA ARORA | 0 | 0.00% | 83,200 | 0.34% |
| | SAJID UMEDALI DHROLIA | 0 | 0.00% | 83,200 | 0.34% |
| | KULBHUSHAN PARASHAR | 0 | 0.00% | 83,200 | 0.34% |
| | ANURADHA HARSHAL MORDE | 0 | 0.00% | 83,200 | 0.34% |
| | REX EQUITY | 0 | 0.00% | 83,200 | 0.34% |
| | KALAWATI KISHOR THAKKAR | 0 | 0.00% | 80,000 | 0.33% |
| | SUNIL POPATLAL NAHAR | 0 | 0.00% | 66,600 | 0.27% |
| | RASHMI YASHDEEP JOSHI | 0 | 0.00% | 60,000 | 0.24% |
| | BHAVNA GOTHI | 0 | 0.00% | 50,000 | 0.20% |
| | MUKKTA NEVILLE MANECKJI | 0 | 0.00% | 50,000 | 0.20% |
| | VIKAS ARORA | 0 | 0.00% | 50,000 | 0.20% |
| | ABHAY PRABHAKAR HAVALDAR | 0 | 0.00% | 50,000 | 0.20% |
| | MALIK AMIRBHAI CHARANIYA | 0 | 0.00% | 49,600 | 0.20% |
| | ASHOK BHAWANDAS AWTANI | 0 | 0.00% | 42,600 | 0.17% |
| | DIVESH WADHAWAN | 0 | 0.00% | 41,600 | 0.17% |
| | NETRADEEP EYE HOSPITAL PRIVATE LTD | 0 | 0.00% | 41,600 | 0.17% |
| | AMISHA NIRAJ VORA | 0 | 0.00% | 41,600 | 0.17% |
| | NERGIS GAURAV PARIKH | 0 | 0.00% | 41,600 | 0.17% |
| | SAROD REALITY PRIVATE LIMITED | 0 | 0.00% | 41,600 | 0.17% |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | | |
|--|---|-------|--------|-------|
| PRATIM SENGUPTA | 0 | 0.00% | 41,600 | 0.17% |
| BIJAL KUNAL THAKKAR | 0 | 0.00% | 37,600 | 0.15% |
| SIDDARTH MURALI KONTHATH | 0 | 0.00% | 33,600 | 0.14% |
| JASPRIT J BUMRAH | 0 | 0.00% | 33,600 | 0.14% |
| SHILPA ASHWIN RANGDAL | 0 | 0.00% | 33,600 | 0.14% |
| VINIT BIPIN SHAH | 0 | 0.00% | 33,600 | 0.14% |
| ROHIT SHARMA | 0 | 0.00% | 33,600 | 0.14% |
| DILIP KESHRIMAL SANKLECHA | 0 | 0.00% | 25,000 | 0.10% |
| CHANDRASHEKHAR RAJARAM KULKARNI | 0 | 0.00% | 20,000 | 0.08% |
| AAMIR KHAN | 0 | 0.00% | 17,600 | 0.07% |
| KANNAN KRISHNAMURTI NAIDU | 0 | 0.00% | 17,600 | 0.07% |
| CHANNA KESHAVA HOSAGAVI | 0 | 0.00% | 16,000 | 0.07% |
| RANBIR RISHI KAPOOR | 0 | 0.00% | 16,000 | 0.07% |
| SHILPA NARENDRA HIRANI | 0 | 0.00% | 16,000 | 0.07% |
| BIMAL PAREKH | 0 | 0.00% | 16,000 | 0.07% |
| KINGSMAN WEALTH MANAGEMENT PRIVATE LIMITED | 0 | 0.00% | 16,000 | 0.07% |
| SUNIL GOVINDLAL BHANDARI | 0 | 0.00% | 16,000 | 0.07% |
| JASKARAN SINGH | 0 | 0.00% | 16,000 | 0.07% |
| KISHORE KANJI THAKKAR | 0 | 0.00% | 16,000 | 0.07% |
| ARUN MAFATLAL PRAJAPATI | 0 | 0.00% | 16,000 | 0.07% |
| BIBHAS DASGUPTA | 0 | 0.00% | 16,000 | 0.07% |
| MANOJ BAVANJIBHAI BAVARIA | 0 | 0.00% | 16,000 | 0.07% |
| AJAY AGNIHOTRI | 0 | 0.00% | 16,000 | 0.07% |
| JYOTSNA MEHTA | 0 | 0.00% | 15,100 | 0.06% |
| MANOJ SHIV LAUNGANI | 0 | 0.00% | 15,000 | 0.06% |
| SHALINI ASHOK CHAWLA | 0 | 0.00% | 13,000 | 0.05% |
| ANKITA CHOPRA | 0 | 0.00% | 12,800 | 0.05% |
| AXE FORTUNE CAPITAL ADVISORS LLP | 0 | 0.00% | 12,800 | 0.05% |
| ABHISHEK NARBARIA | 0 | 0.00% | 12,800 | 0.05% |
| UMESH KUMAR SAHAY | 0 | 0.00% | 12,800 | 0.05% |
| RESHMA MANOJ MOHNANI | 0 | 0.00% | 12,800 | 0.05% |
| RASHMI SARAFF | 0 | 0.00% | 10,000 | 0.04% |
| DINESHKUMAR S RAWLANI | 0 | 0.00% | 9,600 | 0.04% |
| SETHIYA SACHIN KANTILAL | 0 | 0.00% | 9,600 | 0.04% |
| ESHA SAVLANI | 0 | 0.00% | 9,600 | 0.04% |
| S NAGESHWARAN | 0 | 0.00% | 8,000 | 0.03% |
| MINDSCOPE ADVISORS LLP | 0 | 0.00% | 8,000 | 0.03% |
| MUKESH MANOHAR YEOLE | 0 | 0.00% | 8,000 | 0.03% |
| SRINIVASAN ROHINI | 0 | 0.00% | 8,000 | 0.03% |
| ILESH H SANGHANI | 0 | 0.00% | 8,000 | 0.03% |
| ARWA ALVARES | 0 | 0.00% | 8,000 | 0.03% |
| LADDHA NIKHIL RAMESHKUMAR | 0 | 0.00% | 8,000 | 0.03% |
| BHAKTI BIMAL PAREKH | 0 | 0.00% | 8,000 | 0.03% |
| PRANAV NAVINCHANDRA DOCTOR | 0 | 0.00% | 8,000 | 0.03% |
| KALLAM SRINIVAS REDDY | 0 | 0.00% | 8,000 | 0.03% |
| NEELA GOPALAKRISHNAN | 0 | 0.00% | 8,000 | 0.03% |
| WINNER IMPEX PVT LTD | 0 | 0.00% | 8,000 | 0.03% |
| PRAGNESH A SHAH | 0 | 0.00% | 8,000 | 0.03% |
| PARUL KARTIK VAKHARIA | 0 | 0.00% | 8,000 | 0.03% |
| KRISHNAKUMAR | 0 | 0.00% | 8,000 | 0.03% |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | | |
|-------------------------------|---|-------|-------|-------|
| RATANKUMAR MOHTA | | | | |
| NIMISHA GORAKSHAKAR | 0 | 0.00% | 8,000 | 0.03% |
| SUNIL SURESHCHANDRA PHADE | 0 | 0.00% | 8,000 | 0.03% |
| KAPIL DHIRAJ THAKKAR | 0 | 0.00% | 8,000 | 0.03% |
| TAPAS SAHA | 0 | 0.00% | 8,000 | 0.03% |
| MAULALI CHANDSAHEB JAMADAR | 0 | 0.00% | 8,000 | 0.03% |
| AAMER DE | 0 | 0.00% | 8,000 | 0.03% |
| DHANANJAY PUNDLIK WAKUDKAR | 0 | 0.00% | 8,000 | 0.03% |
| SRIRAM JEYARAMAN HUF | 0 | 0.00% | 8,000 | 0.03% |
| VINAY KUMAR | 0 | 0.00% | 8,000 | 0.03% |
| GIRISH PUKHRAJ PORWAL | 0 | 0.00% | 8,000 | 0.03% |
| MUKESH BHAGWANLAL SHINGI | 0 | 0.00% | 8,000 | 0.03% |
| MANISH SHANKARLAL RATHI | 0 | 0.00% | 8,000 | 0.03% |
| SAHAJ BIMAL PAREKH | 0 | 0.00% | 8,000 | 0.03% |
| SAMPATH KUMAR AMUDHA | 0 | 0.00% | 6,400 | 0.03% |
| PONNAKATTI RAJAN UDAY KUMAR | 0 | 0.00% | 6,400 | 0.03% |
| PONNAGATIKUPPUSWAMY JAYARAMAN | 0 | 0.00% | 6,400 | 0.03% |
| PONNAI CHOKALINGAM MANI | 0 | 0.00% | 6,400 | 0.03% |
| JAYANT DIGAMBAR PATKAR | 0 | 0.00% | 6,400 | 0.03% |
| NEHA ALTAMASH AHMED | 0 | 0.00% | 6,400 | 0.03% |
| PRANAY PRITHVIRAJ CHOUHAN | 0 | 0.00% | 6,400 | 0.03% |
| NRIP NIHALANI | 0 | 0.00% | 6,400 | 0.03% |
| VERSHA SHARMA | 0 | 0.00% | 6,400 | 0.03% |
| ASHISH SURJEET MAKHIJANI | 0 | 0.00% | 6,400 | 0.03% |
| MURALI NAGARAJAN | 0 | 0.00% | 6,400 | 0.03% |
| KARAN RAJEEV GOYAL | 0 | 0.00% | 6,400 | 0.03% |
| ROSHAAN MADHUKAR NARKEDAYY | 0 | 0.00% | 6,400 | 0.03% |
| ARCHANA AMAR MULE | 0 | 0.00% | 6,400 | 0.03% |
| VINAYAK CHANDRAKANT SANAS | 0 | 0.00% | 6,400 | 0.03% |
| RAM PRASAD LADI | 0 | 0.00% | 6,400 | 0.03% |
| SHIFA MAKSUD MULANI | 0 | 0.00% | 6,400 | 0.03% |
| SIDDARTH JAIN | 0 | 0.00% | 6,400 | 0.03% |
| SIDDHANT MANGESH DOSHI | 0 | 0.00% | 6,400 | 0.03% |
| ADITYA VIVEK PATKAR | 0 | 0.00% | 6,400 | 0.03% |
| SAMARTH MEHTA | 0 | 0.00% | 5,500 | 0.02% |
| RAJA JEPPEAN | 0 | 0.00% | 5,000 | 0.02% |
| KATTELA RAMESH | 0 | 0.00% | 5,000 | 0.02% |
| SAHIL MEHTA | 0 | 0.00% | 5,000 | 0.02% |
| SHRIKANT LAXMAN KHAJGIWALE | 0 | 0.00% | 4,800 | 0.02% |
| PRASANNA SHRIKANT KHAJGIWALE | 0 | 0.00% | 4,800 | 0.02% |
| ATUL KANTILAL SHAH | 0 | 0.00% | 4,600 | 0.02% |
| KETAN PRAVEEN RANGA | 0 | 0.00% | 4,000 | 0.02% |
| RAKESH PRAKASH SHARMA | 0 | 0.00% | 4,000 | 0.02% |
| THURUPHATI SHEKAR | 0 | 0.00% | 3,200 | 0.01% |
| KARTHIKEYAN BALAKRISHNA | 0 | 0.00% | 3,200 | 0.01% |
| MASILAMANI | 0 | 0.00% | 3,200 | 0.01% |

iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720 | Scrip Code: 534920 | ISIN: INE899M01020

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

| | | | | | | |
|----|------------------|---|---|-------|-------|-------|
| | | NARAYANASWAMY PONNANGATI | | | | |
| | | MOHAN RAO AVANURI | 0 | 0.00% | 3,200 | 0.01% |
| | | GIRIPRASAD NARAYANAN | 0 | 0.00% | 3,200 | 0.01% |
| | | KALIYUR SELVAMANI RAMANUJAM | 0 | 0.00% | 3,200 | 0.01% |
| | | ANSHUL ABHISHEK | 0 | 0.00% | 3,200 | 0.01% |
| | | LOGANATHAN MEENAKSHISUNDARAM | 0 | 0.00% | 3,200 | 0.01% |
| c. | Issue price | For consideration other than cash — Share Swap basis. Fair Value of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited): Rs. 48.20/- per share. Fair Value of iSERA Biological Limited: Rs. 48.20/- per share. Swap Ratio: 1:1 (as certified by Mr. Bhavesh M Rathod, Registered Valuer, in respect of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) and Mr. Karan Chetan Shah, Registered Valuer, in respect of iSERA Biological Limited, vide their respective Valuation Reports dated April 20, 2026). | | | | |
| d. | No. of Investors | 196 (One Hundred and Ninety-Six) | | | | |